[ET Net News Agency, 31 March 2020] CLSA cut its target price for CSPC Pharmaceutical
Group (01093) to HK$22.34 from HK$23.37 considering the ongoing outbreak and slight miss
in the 2019 results. CLSA maintained its "buy" rating.
The research house said CSPC's 2019 attributable net profit of Rmb3,714m (up 20.6%)
missed CLSA's profit growth forecast of 24.1%. It believes the company would still succeed
due to its strong promotion network and rapid growth in oncology drugs. (KL)